Every biopharmaceutical product touches dozens of materials before it reaches a consumer. Understanding what those materials give off, and whether any of it ends up in the finished product, is one of the most critical questions in modern product safety.
In the biopharmaceutical world, a product is only as safe as everything it has ever touched. From the moment a biological molecule is synthesized in a manufacturing facility to the moment it reaches the end consumer, it passes through a complex chain of materials: plastic tubing, rubber stoppers, glass vials, filters, stainless steel vessels, and single-use bags. The science of leachables and extractables asks a fundamental question: is anything from those materials migrating into the finished product?
While E&L analysis is perhaps best known in the pharmaceutical and biopharmaceutical space, it also applies to other industries. The food industry, cosmetics manufacturers, and medical device companies all face the same core challenge: ensuring that the materials their products contact during manufacturing, packaging, and storage do not introduce unwanted chemical migrants. Anywhere a product touches a container, a filter, a seal, or a processing surface, the principles of extractables and leachables apply.
Put simply: extractables map out the universe of possible risks, while leachables confirm what is actually happening in the final product. Leachables are typically a subset of extractables, representing the real-world, lower-intensity version of a worst-case stress test. And crucially, the risk does not stop at pharmaceuticals: the same migration science applies to a food pouch, a cosmetic tube, or a medical implant.
Think of it like a new plastic storage container. If you fill it with boiling vinegar for 24 hours, whatever leaches out represents extractables — the maximum it could ever release under stress. If you use it normally to store food over a year, whatever ends up in the food represents leachables — what is actually reaching you.
The stakes in biopharma are uniquely high. Unlike traditional small-molecule products, biopharmaceuticals, including monoclonal antibodies, vaccines, gene therapies, and cell therapies, are large, complex molecules that are particularly sensitive to their environment. Even trace quantities of a migrating chemical can trigger serious consequences for manufacturers and consumers alike.
For consumers, migrated substances can cause immune reactions, including potentially serious responses in vulnerable populations. They can make the biological molecule less stable by causing proteins to clump together, which makes the product work less well. They can act as direct toxicants, particularly in injectable or inhalable products that bypass the body's natural filters. And they can quietly degrade product quality in ways that are invisible to the end user but detectable to regulators.
For manufacturers, the consequences are commercial as well as scientific. Regulatory frameworks including USP 661, 1663, 1664, and ICH Q3E guidelines, as well as the BPOG/BioPhorum guidance documents set binding standards that must be met before any biopharmaceutical product can reach market. Failure to address E&L can mean delayed approvals, costly reformulations, or damaging product recalls.
Migration doesn't happen randomly. It is driven by chemistry, time, temperature, and contact. The same physical laws that govern how a tea bag steeps in hot water govern how packaging chemicals move into a finished product. Here are some of the most common pathways in a biopharmaceutical context:
Bioreactor bags, mixing vessels, and transfer tubing made from polyethylene or EVA can release antioxidants, plasticizers, and processing aids directly into drug substance solutions during manufacturing. These are among the most studied leachable sources in modern bioprocessing.
Vial stoppers are a classic source of leachables in injectable products. Vulcanizing agents, accelerators, and extractable nitrosamines can migrate from elastomeric components into a drug product over its shelf life especially in aqueous or slightly acidic formulations. The consumer never sees the stopper, but they may be exposed to what it gives off.
Sterilizing-grade filters used in final bioburden reduction steps can shed residual surfactants, wetting agents, and membrane material components. Because filtration occurs at a late manufacturing stage, any leachable introduced here has minimal opportunity to be removed before the product reaches the consumer.
The FDA has actively investigated migration of nitrosamine compounds such as NDBA from printed overwraps and infusion bag pouches into the drug product contained within. Ink components and adhesives are an underappreciated leachable source that has drawn increasing regulatory scrutiny.
Upstream purification steps using protein A resins, ion exchange columns, and stainless steel tanks can contribute metal ions, ligand fragments, and cleaning agent residues that carry through the purification train if not properly characterized and controlled.
Combination products that pair a biopharmaceutical with a delivery device face dual regulatory scrutiny. Silicone oil used to lubricate syringe barrels, tungsten residues from the barrel-forming process, and adhesive components from needle shields are all documented leachable sources in the combination product space.
The consequences of overlooking E&L are not theoretical. In 2010, McNeil Consumer Healthcare voluntarily recalled more than 500 lots of Tylenol, Motrin, Benadryl, and Zyrtec after consumers began reporting an unusual musty odor in the products. The source of the problem was eventually traced not to the product formulations themselves, but to the packaging supply chain.
An antifungal chemical used to treat wooden shipping pallets had volatilized and migrated through the outer cardboard packaging, through the bottle closures, and into the products themselves. The culprit was 2,4,6-tribromoanisole (TBA), a suspected carcinogen. The recall ultimately cost the manufacturer an estimated $900 million in lost sales and triggered a years-long FDA consent decree.
What makes this case so instructive is where the contamination originated: not from a vial stopper or a manufacturing vessel, but from wooden shipping pallets sitting in a warehouse. It is a stark reminder that the E&L risk chain extends far beyond the manufacturing floor. Any material in the supply chain that comes into proximity with a finished product, even indirectly, is a potential source. The companies that protect themselves are the ones that map that chain thoroughly and test proactively rather than reactively.
Similar scrutiny followed revelations about polycyclic aromatic hydrocarbons (PAHs) leaching from seals in metered-dose inhalers during the 1990s, compounds associated with increased cancer risk that had gone undetected until the FDA began actively investigating inhaler component chemistry. In both cases, the problem was not a lack of good intentions: it was a lack of systematic analytical investigation.
RJ Lee Group brings an industrial forensics mindset to pharmaceutical and biopharmaceutical E&L challenges. As a cGMP-compliant, ISO 17025-certified, FDA-registered analytical testing laboratory, RJ Lee Group deploys advanced instrumentation and multidisciplinary scientific expertise to identify, characterize, and trace contaminants back to their source, giving manufacturers the data they need to protect consumers and maintain regulatory standing.
Identifying and fully characterizing unwanted particles in biopharmaceutical products using RJ Lee Group's industrial forensics approach, tracing particles back to their manufacturing source with pinpoint accuracy.
Using state-of-the-art instrumentation to determine not just what a contaminant is, but where it came from whether packaging, process equipment, or a single-use component.
High-resolution imaging paired with elemental analysis to characterize particle morphology, size, and composition: an essential tool for both extractables screening and leachable attribution.
A full suite of separation and detection technologies including HPLC, GC, LC-MS, ICP-MS, ICP-AES, and IC to detect and quantify organic and inorganic compounds at trace levels in complex biopharmaceutical matrices.
Critical characterization of active ingredients, excipients, and contaminant particles that impact both manufacturing process performance and finished product quality.
Expert guidance navigating FDA, EMA, and USP requirements, providing the analytical data packages and documentation needed for product approval submissions and ongoing quality assurance programs.
Going beyond detection to determine the origin of particulate or chemical contamination, enabling manufacturers to implement targeted corrective and preventive actions (CAPAs).
Evaluating raw materials, packaging components, and process equipment to understand their chemical composition and potential for contributing extractables under both exaggerated and real-use conditions.
RJ Lee Group's team operates across pharmaceuticals, biotechnology, and medical devices, giving clients a partner who understands the full product lifecycle, from early material qualification through post-market surveillance. Their FDA-registered, ISO 17025-certified laboratory infrastructure ensures that data generated is defensible, audit-ready, and built to regulatory expectations.